With buzzy medications like Ozempic and Mounjaro making headlines for blood sugar management, it’s easy to forget that some medications have been helping patients with type 2 diabetes for decades.

Metformin blunted exercise-induced improvements in vascular insulin sensitivity, aerobic fitness, inflammatory markers, and fasting glucose levels in adults at high risk for metabolic syndrome, ...

Rutgers scientists found that metformin can blunt many of the metabolic and cardiovascular improvements normally produced by exercise. Participants who took the drug saw reduced gains in fitness, ...

A common diabetes drug could dampen some of the key benefits of exercise, a new study has found. Researchers from Rutgers University discovered that adults who took metformin, a widely used generic ...

The song has been streamed over 3 million times in under a month. A song created through artificial intelligence has made history topping a Billboard country music chart, but it has also sent ...

A hospital in Thailand created a quick-action dialysis protocol for patients with metformin-associated lactic acidosis, a dangerous reaction to a common diabetes drug. The program sharply reduced ...

A widely prescribed diabetes drug may be sabotaging one of the most trusted strategies for preventing the disease: exercise. That is the conclusion of a Rutgers-led study published in The Journal of ...

Metformin vs. Ozempic: What’s the Difference? Metformin (Fortamet, Glumetza) and semaglutide (Ozempic, Rybelsus) are medicines that treat type 2 diabetes. They both lower blood sugar, but they work ...

Metformin is a generic prescription drug that works to treat type 2 diabetes by helping lower your blood sugar levels. Your response to this drug may vary based on your medical history and diagnosis.

Metformin is an unassuming hero of modern medicine. For more than 60 years, this humble pill has been a mainstay of diabetes care, helping millions of people manage their blood sugar. It lowers blood ...

CEO Sam Altman called a strange graph in its GPT-5 presentation a ‘mega chart screwup.’ CEO Sam Altman called a strange graph in its GPT-5 presentation a ‘mega chart screwup.’ is a senior reporter ...